Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 1/20 | 0.51 |
| ▸ | HTR1B | P28222 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19405089 | 0.91 | HTR1D (0.53) | HTR1DHTR1BL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL19384148 | 0.87 | KDM4E (0.43) | L3MBTL1SMN1; SMN2LMNAALDH1A1KDM4E | |
| SCHEMBL19384145 | 0.82 | HDAC1 (0.38) | L3MBTL1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL19384155 | 0.82 | HTR1D (0.56) | HTR1DHTR1BL3MBTL1IKBKBSMN1; SMN2 | |
| SCHEMBL19384158 | 0.76 | HTR1D (0.53) | HTR1DHTR1BL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL450708 | 0.75 | HTT (0.47) | L3MBTL1SMN1; SMN2ATMMEN1KMT2A | |
| SCHEMBL3466840 | 0.72 | KDM4E (0.45) | L3MBTL1SMN1; SMN2LMNAALDH1A1KDM4E | |
| SCHEMBL19384179 | 0.71 | POLB (0.53) | HTR1DHTR1BL3MBTL1IKBKBSMN1; SMN2 | |
| SCHEMBL3345807 | 0.71 | SMN1; SMN2 (0.68) | L3MBTL1SMN1; SMN2LMNAATMTSHR | |
| SCHEMBL10002496 | 0.71 | LMNA (0.53) | L3MBTL1SMN1; SMN2LMNAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190100498-A1 | CRYSTALLINE FORM | ASTRAZENECA AB (SE) | 2019-04-04 | — | — | US | disclosed |
| US-20190100498-A1 | CRYSTALLINE FORM | ASTRAZENECA AB (SE) | 2019-04-04 | — | — | US | disclosed |
| EP-3433237-A1 | CRYSTALLINE FORM | Astrazeneca AB (SE) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017162304-A1 | CRYSTALLINE FORM | ASTRAZENECA AB (SE) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017162304-A1 | CRYSTALLINE FORM | ASTRAZENECA AB (SE) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100498-A1 | CRYSTALLINE FORM | GYS2, PYGL, SFPQ | HTR1D 4734/4885HTR1B 4554/4885L3MBTL1 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.